Kevin Kinsella founded Avalon in 1983. He has specialized in the formation, financing and/or development of more than 60 early-stage companies, including: Athena Neurosciences (acquired by Elan Corporation, plc (NYSE: ELN)); Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX); Sequana Therapeutics (NYSE: CRA); Vertex Pharmaceuticals, Inc. (Nasdaq: VRTX); Synaptics, Inc. (Nasdaq: SYNA); Vocera Communications (NYSE: VCRA); and Sytera Ophthalmics Inc. (acquired by Sirion Therapeutics). Mr. Kinsella was the founding chairman of Athena Neurosciences, Aurora Biosciences Corporation, Landmark Graphics, NeoRx, Onyx Pharmaceuticals, Inc., Synaptics, Vertex Pharmaceuticals, X-Ceptorand Sequana Therapeutics.

Mr. Kinsella is a graduate of the Massachusetts Institute of Technology (MIT) with a Bachelor of Science degree in management, with minors in electrical engineering and political science. He holds a Master of Arts degree in International Relations from the Johns Hopkins School of Advanced International Studies (SAIS) and conducted post-graduate work in political economy on a Rotary International Fellowship at the University of Stockholm, Sweden.

Mr. Kinsella is a member of the Boards of Directors of Ankasa Regenerative Medicine, Jnana Therapeutics, and Eikonizo Therapeutics.